Caplin Point is a fast growing, fully integrated Pharmaceutical company with a dominant presence in Latin America, Francophone Africa and a growing presence in the Regulated markets such as USA and EU. The facility has been inspected by US FDA three times since 2016 and received EIR each time. As on date, the company has filed 41 ANDAs, with 28 approvals. The facility is also approved by EU-GMP, ANVISA-Brazil, INVIMA-Colombia, COFEPRIS-Mexico, etc. Caplin Point maintains deep focus on innovative technologies and products, with a sizeable part of its annual earnings invested into Research & Development of safe and effective products across varied dosage forms.
Caplin Point是一家快速发展的综合性制药公司，在拉丁美洲和非洲法语国家占据显著地位，并且在美国和欧盟等规范市场的影响力也与日俱增。自 2016 年以来，该公司的生产设施已接受美国FDA三次检查，均获得了EIR。截至目前，该公司已提交 41 份ANDA申请，其中 28 份已获批。该生产设施还获得了欧盟的EU-GMP、巴西ANVISA、哥伦比亚的INVIMA和墨西哥的COFEPRIS等机构的批准。Caplin Point专注于技术与产品的创新，每年将相当一部分收益投入到各种剂型的安全有效产品的研发中。
